The present disclosure describes analog conotoxin peptides of the a-contoxin peptide RglA. These analog conotoxin peptides block the a9al0 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.